News

Choose the legacy retirement plan or go with the new blended plan?

Insys Therapeutics could become the first corporate casualty of the opioid epidemic, collapsing under legal expenses and plummeting sales.

Three of the lawmakers who will lead the House next year as Congress focuses on skyrocketing drug costs are among the biggest recipients of campaign contributions from the pharmaceutical industry.

An email campaign from the CMS appears to be encouraging enrollees to opt for private Medicare Advantage plan instead of original Medicare.

A U.S. District judge said it would be “more than reasonable” for CVS and Aetna to keep their businesses separate while he reviews the acquisition.

Patients are increasingly seeking information from their doctor about what treatment will cost them, but providers are unprepared for such conversations.